Updates
** Applied Therapeutics' APLT.O shares fall 72.1% to $2.39, set for a record single-day drop
** The U.S. FDA on Wednesday declined to approve APLT's drug to treat galactosemia, a rare genetic metabolic disease
** The FDA's letter cited "deficiencies in the clinical application" for the drug, called govorestat, APLT says
** Brokerage William Blair says the letter was "unexpected and disappointing" but believes it does not increase the regulatory risk for govorestat's approval for SORD deficiency, another rare genetic metabolic condition
** Including session's losses, stock down 28.4% YTD
(Reporting by Kamal Choudhury)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。